CHAM
ALLO icon

Clear Harbor Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Clear Harbor Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8K Hold
10,000
– – ﹤0.01% 448
2026
Q1 		$24.4K Hold
10,000
– – ﹤0.01% 443
2025
Q4 		$13.7K Buy
+10,000
New +$13.2K ﹤0.01% 444

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Clear Harbor Asset Management's ALLO Position: Q2 2026 in Review

Clear Harbor Asset Management held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 10,000 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #448.

Clear Harbor Asset Management first reported a position in ALLO in Q4 2025 and has held it in 3 quarters since. The position peaked at $24.4K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Clear Harbor Asset Management held 10,000 shares of Allogene Therapeutics worth $20.8K as of Q2 2026.
  • Clear Harbor Asset Management left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Clear Harbor Asset Management's portfolio in Q2 2026, its #448 holding.
  • Clear Harbor Asset Management first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Clear Harbor Asset Management's Allogene Therapeutics position peaked at $24.4K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Clear Harbor Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.